- Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
- Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
- Regeneron Announces Investor Conference Presentations
- Regeneron Reports First Quarter 2024 Financial and Operating Results
- EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
- Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
- Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
- Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
- Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
- Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
More ▼
Key statistics
As of last trade Regeneron Pharmaceuticals Inc (REGN:NSQ) traded at 974.00, -2.44% below its 52-week high of 998.33, set on Feb 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 978.27 |
---|---|
High | 978.30 |
Low | 971.78 |
Bid | 973.94 |
Offer | 974.96 |
Previous close | 978.21 |
Average volume | 457.28k |
---|---|
Shares outstanding | 110.19m |
Free float | 106.54m |
P/E (TTM) | 28.59 |
Market cap | 106.66bn USD |
EPS (TTM) | 33.86 USD |
Data delayed at least 15 minutes, as of May 16 2024 17:49 BST.
More ▼